TABLE 4.

Clinical factors that are determinants of choice of therapy

Factor	C → LR vs. LR		PC vs. LR		PC vs. C→ LR		P value
	OR	95 % CI	OR	95 % CI	OR	95 % CI
Age (years)
55	Ref.		Ref.		Ref.		<0.001
75	1.42	1.13–1.79	2.30	1.62–3.26	1.62	1.23–2.14
ECOG performance status
0	Ref.		Ref.		Ref.		<0.001
2	1.73	1.34–2.23	4.62	2.96–7.24	2.68	1.85–3.88
Tumor presentation (month)
Metachronous, 25	Ref.		Ref.		Ref.		<0.001
Metachronous, 11	1.48	1.11–1.96	1.42	0.93–2.16	0.96	0.66–1.40
Synchronous	4.27	2.94–6.21	3.10	1.88–5.11	0.73	0.48–1.09
Tumor number and location
1 tumor, single lobe	Ref.		Ref.		Ref.		<0.001
1 tumor, centrally located	2.84	1.96–4.13	2.69	1.50–4.85	0.95	0.58–1.56
3 tumors, single lobe	2.02	1.41–2.90	2.51	1.37–4.58	1.24	0.74–2.07
3 tumors, both lobes	3.21	2.14–4.81	4.13	2.16–7.88	1.29	0.73–2.27
5 tumors, single lobe	2.31	1.59–3.37	3.88	2.14–7.04	1.68	1.00–2.81
5 tumors, both lobes	5.12	3.26–8.04	9.60	5.08–18.2	1.88	1.11–3.17
Tumor size (largest metastasis) (cm)
2	Ref.		Ref.		Ref.		<0.001
4	1.49	1.12–2.00	2.01	1.31–3.08	1.34	0.95–1.89
6	1.70	1.26–2.29	2.40	1.62–3.54	1.41	1.00–1.99
Extent of resection required (%)
30	Ref.		Ref.		Ref.		0.002
45	1.06	0.81–1.39	0.94	0.62–1.43	0.89	0.63–1.27
60	1.66	1.23–2.23	1.99	1.32–2.99	1.20	0.84–1.71
Extrahepatic disease
None	Ref.		Ref.		Ref.		<0.001
Resectable solitary lung	4.43	3.24–6.04	6.97	4.30–11.3	1.57	1.02–2.43
Hilar/hepato-duodenal nodes	8.92	6.00–13.3	49.9	28.4–87.8	5.60	3.62–8.64

LR immediate liver resection, C → LR preoperative chemotherapy followed by surgery, PC palliative chemotherapy, OR odds ratio, CI confidence interval, Ref. referent, ECOG Eastern Cooperative Oncology Group